@article{359eee4f63744352ace3035aad4bcbc4,
title = "Cholesterol absorption inhibitor ezetimibe: Risk-benefits and role in treating dyslipidemias",
author = "Shizuya Yamashita and Daisaku Masuda and Akifumi Matsuyama",
note = "Funding Information: Acknowledgments The authors gratefully acknowledge the excellent technical assistance and office work extended by Kaori Hizu-Shioyama, Risa Wada, and Kyoko Ozawa. This work was supported by a Grant-in-Aid for Scientific Research (No. 13671191) to S. Yamashita from the Japanese Ministry of Education, Science, Sports and Culture and in part by the Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (NIBIO), Foundation for Biomedical Research and Innovation for Akifumi Matsuyama, Daisaku Masuda, Shizuya Yamashita. Funding Information: S. Yamashita has received honoraria and grant support from MSD and Bayer Co., Ltd. Other coauthors have nothing to disclose. Copyright: Copyright 2017 Elsevier B.V., All rights reserved.",
year = "2015",
doi = "10.1007/978-1-60761-424-1_28",
language = "English",
volume = "1",
pages = "465--481",
journal = "Contemporary Endocrinology",
issn = "0196-8653",
publisher = "Humana Press",
}